Mostrar el registro sencillo del ítem

dc.contributor.authorPicardo, F.
dc.contributor.authorRomanelli, A.
dc.contributor.authorMuinelo Romay , Laura
dc.contributor.authorMazza, T.
dc.contributor.authorFusilli, C.
dc.contributor.authorParrella, P.
dc.contributor.authorBarbazán, J.
dc.contributor.authorLópez López, Rafael 
dc.contributor.authorBarbano, R.
dc.contributor.authorDe Robertis, M.
dc.contributor.authorTaffon, C.
dc.contributor.authorBordoni, V.
dc.contributor.authorAgrati, C.
dc.contributor.authorCostantini, M.
dc.contributor.authorRicci, F.
dc.contributor.authorGraziano, P.
dc.contributor.authorMaiello, E.
dc.contributor.authorMuscarella, L. A.
dc.contributor.authorFazio, V. M.
dc.contributor.authorPoeta, M. L.
dc.date.accessioned2021-11-30T11:12:22Z
dc.date.available2021-11-30T11:12:22Z
dc.date.issued2019
dc.identifier.issn2072-6694
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31635093es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15780
dc.description.abstractEpigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95% CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100% specificity and a 50% sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDiagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal canceren
dc.typeArtigoes
dc.authorsophosPicardo, F.
dc.authorsophosRomanelli, A.
dc.authorsophosMuinelo-Romay, L.
dc.authorsophosMazza, T.
dc.authorsophosFusilli, C.
dc.authorsophosParrella, P.
dc.authorsophosBarbazán, J.
dc.authorsophosLopez-López, R.
dc.authorsophosBarbano, R.
dc.authorsophosDe Robertis, M.
dc.authorsophosTaffon, C.
dc.authorsophosBordoni, V.
dc.authorsophosAgrati, C.
dc.authorsophosCostantini, M.
dc.authorsophosRicci, F.
dc.authorsophosGraziano, P.
dc.authorsophosMaiello, E.
dc.authorsophosMuscarella, L. A.
dc.authorsophosFazio, V. M.
dc.authorsophosPoeta, M. L.
dc.identifier.doi10.3390/cancers11101598
dc.identifier.pmid31635093
dc.identifier.sophos31808
dc.issue.number10es
dc.journal.titleCancers (Basel)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.page.initial1598es
dc.relation.publisherversionhttps://res.mdpi.com/d_attachment/cancers/cancers-11-01598/article_deploy/cancers-11-01598.pdfes
dc.rights.accessRightsopenAccesses
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number11es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional